Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Endocr Metab Immune Disord Drug Targets. 2022;22(1):143-158. doi: 10.2174/1871530321666210121154037.
BACKGROUND & AIM: This meta-analysis was performed to quantify the effects of probiotics on renal and glycemic biomarkers among patients with Diabetic Nephropathy (DN).
Electronic databases were searched on May 10, 2020. All trials that investigated the effect of probiotics on serum glycemic markers (Fasting Plasma Glucose [FPG], Hemoglobin A1C, Insulin, Homeostatic Model Assessment-Insulin Resistance [HOMA-IR], and Quantitative Insulin Sensitivity Check Index [QUICKI]), and renal status markers (Creatinine [Cr], Blood Urea Nitrogen [BUN], and Glomerular Filtration Rate [GFR]) were included.
Seven trials that included 340 patients were identified for analysis. The results indicated that probiotics significantly reduced FPG (WMD= -19.08 mg/dl; 95% CI= -32.16, -5.99; P=0.004), HOMA-IR (WMD= -1.88; 95% CI= -3.63, -0.12; P=0.036), and Cr (WMD= -0.18 mg/dl; 95% CI= -0.26, -0.09; P<0.001) levels in DN patients; however, there was no statistically significant change in Hemoglobin A1C, Insulin, QUICKI, BUN, and GFR.
This meta-analysis supports the potential use of probiotics in the improvement of some glycemic and renal biomarkers in patients with DN.
本荟萃分析旨在量化益生菌对糖尿病肾病（DN）患者的肾脏和血糖生物标志物的影响。
于 2020 年 5 月 10 日检索电子数据库。纳入所有研究益生菌对血糖标志物（空腹血糖[FPG]、糖化血红蛋白、胰岛素、稳态模型评估-胰岛素抵抗[HOMA-IR]和定量胰岛素敏感性检查指数[QUICKI]）和肾脏状态标志物（肌酐[Cr]、血尿素氮[BUN]和肾小球滤过率[GFR]）的影响的试验。
确定了 7 项纳入 340 名患者的试验进行分析。结果表明，益生菌可显著降低 FPG（WMD=-19.08mg/dl；95%CI=-32.16，-5.99；P=0.004）、HOMA-IR（WMD=-1.88；95%CI=-3.63，-0.12；P=0.036）和 Cr（WMD=-0.18mg/dl；95%CI=-0.26，-0.09；P<0.001）水平，但对糖化血红蛋白、胰岛素、QUICKI、BUN 和 GFR 无统计学意义上的变化。
本荟萃分析支持益生菌在改善 DN 患者某些血糖和肾脏生物标志物方面的潜在应用。
